NYSEAMERICAN:XXII - 22nd Century Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.75 -0.05 (-2.78 %)
(As of 03/25/2019 02:01 PM ET)
Previous Close$1.80
Today's Range$1.71 - $1.83
52-Week Range$1.58 - $3.29
Volume1.25 million shs
Average Volume1.93 million shs
Market Capitalization$218.13 million
P/E RatioN/A
Dividend YieldN/A
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM, a line of research cigarettes for use in independent clinical studies. The company's products under development include BRAND A, a very low nicotine cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette. In addition, it engages in contract manufacturing business for third-party branded tobacco products. The company has scientific collaborations with the University of Virginia and Anandia Laboratories, Inc. to develop proprietary hemp strains with less than 0.3% dry weight content of delta-9-tetrahydrocannabinol. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.

Receive XXII News and Ratings via Email

Sign-up to receive the latest news and ratings for XXII and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Market Cap$218.13 million
Next Earnings Date5/2/2019 (Estimated)

22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions

What is 22nd Century Group's stock symbol?

22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."

How were 22nd Century Group's earnings last quarter?

22nd Century Group Inc (NYSEAMERICAN:XXII) released its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $6.26 million for the quarter. View 22nd Century Group's Earnings History.

When is 22nd Century Group's next earnings date?

22nd Century Group is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for 22nd Century Group.

What price target have analysts set for XXII?

1 Wall Street analysts have issued twelve-month price targets for 22nd Century Group's stock. Their forecasts range from $11.50 to $11.50. On average, they anticipate 22nd Century Group's stock price to reach $11.50 in the next year. This suggests a possible upside of 559.0% from the stock's current price. View Analyst Price Targets for 22nd Century Group.

What is the consensus analysts' recommendation for 22nd Century Group?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 22nd Century Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for 22nd Century Group.

What are Wall Street analysts saying about 22nd Century Group stock?

Here are some recent quotes from research analysts about 22nd Century Group stock:
  • 1. Chardan Capital analysts commented, "We believe it is most likely the NPRM on mandating a non-addictive level of nicotine in combustible cigarettes will wait for a new Commissioner." (3/15/2019)
  • 2. According to Zacks Investment Research, "22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. " (8/16/2018)

Has 22nd Century Group been receiving favorable news coverage?

News stories about XXII stock have been trending positive on Monday, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. 22nd Century Group earned a news impact score of 3.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.

Are investors shorting 22nd Century Group?

22nd Century Group saw a decrease in short interest during the month of February. As of February 28th, there was short interest totalling 21,262,904 shares, a decrease of 1.9% from the February 15th total of 21,665,396 shares. Based on an average daily volume of 1,117,008 shares, the short-interest ratio is currently 19.0 days. Approximately 18.8% of the company's stock are short sold. View 22nd Century Group's Current Options Chain.

Who are some of 22nd Century Group's key competitors?

What other stocks do shareholders of 22nd Century Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 22nd Century Group investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), Cronos Group (CRON), Aurora Cannabis (ACBFF), Micron Technology (MU), Terra Tech (TRTC), GW Pharmaceuticals PLC- (GWPH), Aurora Cannabis (ACB), KushCo (KSHB) and Novavax (NVAX).

Who are 22nd Century Group's key executives?

22nd Century Group's management team includes the folowing people:
  • Mr. Henry Sicignano III, Pres, CEO & Director (Age 51)
  • Mr. John T. Brodfuehrer, CFO & Treasurer (Age 61)
  • Mr. Thomas L. James Esq., VP, Gen. Counsel & Sec. (Age 60)
  • James Vail, Director of Communications
  • Dr. Paul J. Rushton, VP of Plant Biotechnology (Age 56)

Who are 22nd Century Group's major shareholders?

22nd Century Group's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.49%), ETF Managers Group LLC (3.67%), Northern Trust Corp (1.04%), Geode Capital Management LLC (0.94%), Geode Capital Management LLC (0.94%) and Bank of New York Mellon Corp (0.33%). Company insiders that own 22nd Century Group stock include Michael Robert Moynihan and Thomas L James. View Institutional Ownership Trends for 22nd Century Group.

Which institutional investors are selling 22nd Century Group stock?

XXII stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Northern Trust Corp, NJ State Employees Deferred Compensation Plan and National Asset Management Inc.. View Insider Buying and Selling for 22nd Century Group.

Which institutional investors are buying 22nd Century Group stock?

XXII stock was acquired by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Geode Capital Management LLC, Geode Capital Management LLC, BlackRock Inc., Bank of New York Mellon Corp, Advisory Services Network LLC, MetLife Investment Advisors LLC and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. View Insider Buying and Selling for 22nd Century Group.

How do I buy shares of 22nd Century Group?

Shares of XXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is 22nd Century Group's stock price today?

One share of XXII stock can currently be purchased for approximately $1.7450.

How big of a company is 22nd Century Group?

22nd Century Group has a market capitalization of $217.50 million.

What is 22nd Century Group's official website?

The official website for 22nd Century Group is http://www.xxiicentury.com/.

How can I contact 22nd Century Group?

22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.

MarketBeat Community Rating for 22nd Century Group (NYSEAMERICAN XXII)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  256 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  475
MarketBeat's community ratings are surveys of what our community members think about 22nd Century Group and other stocks. Vote "Outperform" if you believe XXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XXII will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel